Kytopen Partners with Cambridge Consultants on Flowfect
Genetic Engineering and Biotechnology News | January 28, 2020
MIT spin-out company Kytopen signed a deal with Cambridge Consultants to co-develop the FlowfectTM system, a scalable process that reportedly yields billions of engineered cells in minutes. The product will streamline the engineering of a wide array of human and human-derived cells for use in next-generation cell therapies, with the goal of expanding access to new medicines, says Paulo Garcia, CEO and co-founder of Kytopen.